How do I buy Novartis (NVS) stock?

Buying Novartis (NVS) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "NVS", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy NVS by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if NVS is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Novartis (NVS) Stock

Q: What is the minimum investment for NVS on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Novartis from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NEW YORK STOCK EXCHANGE, INC. · NVS

Trade NVS

Key stats

Market cap: $285.83B
Price / Earnings ratio: 21.9x
EPS (TTM): $6.66
Volume: Loading
52-week high: $170.46
52-week low: $121.57
EPS vs analyst estimate: -1.7%Q3 FY25 · $2.25 vs $2.29
Next earnings report: 27 Oct 2026

Source: third-party data provider, as of October 17, 2026

EPS estimate: analyst consensus

Compare with NVS

Technical indicators

RSI 14: 62.02
MACD 12/26/9: -0.30
EMA 9 of MACD: -1.40
MACD histogram: 1.10
SMA 50: $148.31; Price above SMA 50
EMA 50: $146.85; Price above EMA 50
SMA 200: $151.04; Price below SMA 200
EMA 200: $146.98; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Hold

Based on 1 analyst rating

Strong Sell0

Sell0

Hold1

Buy0

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2025

68B45B22B0

Debt & Balance Sheet

Total assets

Total liabilities

2025

133B88B44B0

Revenue to Profit

2025

$56.7B

Revenue

$0.0

Cost of revenue

$43.0B

Gross profit

$0.0

Operating expenses

$14.0B

Net income

Earnings

EPS forecast

Actual EPS

$2.25

$2.29

Q3FY25

$1.94

Q4FY25

$2.26

Q1FY26

$2.49

Q2FY26

$2.27

Q3FY26

The market is expecting earnings per share of $2.27 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.

SectorHealthcare

IndustryDrug Manufacturers - General

Employees75,267

CEODr. Vasant Narasimhan M.D.

IPO DateNov 18, 1991

HeadquartersBasel, Switzerland

Key Executives

Name	Title	Year Born
Dr. Vasant Narasimhan M.D.	Chief Executive Officer	1976
Mr. Mukul Mehta	Chief Financial Officer	1973
Mr. Victor Bulto	President of US	1978
Dr. Patrick Horber M.D.	President of International	1970
Dr. Steffen Lang Ph.D.	President of Operations	1967
Paul Penepent	Head of Group Financial Reporting and Accounting	—
Ms. Sloan Simpson	Global Head of Investor Relations	—
Ms. Karen L. Hale	Chief Legal & Compliance Officer	1968
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer	1968
Mr. Evan Beckman	Global Head of Translational Medicine at Novartis Institute for BioMedical Research	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021										+0.5	-5.2	+9.6
2022	-1.1	-0.8	+0.7	+0.4	+3.8	-5.7	+1.7	-6.0	-5.4	+5.8	+10.5	+1.0
2023	-1.7	-4.7	+9.8	+10.9	-6.1	+3.9	+6.2	-2.7	+1.1	-7.8	+3.9	+2.9
2024	+2.4	-4.1	-5.2	+1.3	+5.8	+3.6	+4.6	+7.8	-2.9	-5.4	-3.3	-7.1
2025	+7.8	+3.4	+0.8	+3.5	+4.0	+3.7	-7.6	+9.8	+1.3	-6.0	+5.3	+6.9
2026	+7.3	+11.6	-8.5	-4.7	+2.5	+7.6	+1.3	-1.0	-11.6	+6.6

Stocks in the same sector

FAQ

Buying Novartis (NVS) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "NVS", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy NVS by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Novartis from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Yes, Novartis regularly pays dividends to shareholders. Currently, the estimated dividend yield for NVS is around 2.06% per year. On Gotrade, cash dividends will be automatically credited to your account balance (after taxes).

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Novartis (NVS) Stock

Key stats

Compare with NVS

Recent news

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

US FDA expands use of Novartis drug for chronic skin condition

US FDA expands use of Novartis drug for chronic skin condition

Focus: AI companies run virtual drug trials, aim to improve success of human studies

Focus: AI companies run virtual drug trials, aim to improve success of human studies

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

US FDA expands use of Novartis drug for chronic skin condition

US FDA expands use of Novartis drug for chronic skin condition

Focus: AI companies run virtual drug trials, aim to improve success of human studies

Focus: AI companies run virtual drug trials, aim to improve success of human studies

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals

Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals

Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Novartis signs mRNA deal for about $7.8 billion with China's Abogen

Novartis signs mRNA deal for about $7.8 billion with China's Abogen

Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines

Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

European drugmakers call for faster trials, more spending to compete with US, China

European drugmakers call for faster trials, more spending to compete with US, China

About Novartis

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Corporate actions

Upcoming

Past

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade